Sarueda, Carla D.

HRN: 04-69-17  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/21/2022
CEFUROXIME 500MG (TAB)
12/21/2022
12/28/2022
ORAL
500mg
Q12
UTI
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Urinary TractSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: